Healthcare-associated infections (HAIs) affect 1 in 31 hospitalized patients on any given day — accounting for 98,987 deaths annually in the US (CDC, 2020) and $28–33 billion in excess healthcare costs. MRSA (methicillin-resistant Staphylococcus aureus) and Clostridioides difficile represent the most preventable and highest-burden HAIs in US hospitals, with evidence-based prevention bundles significantly reducing incidence when consistently implemented.
MRSA Prevention: The REDUCE MRSA Trial
The REDUCE MRSA trial (Huang et al., 2013, NEJM, n=74,256 ICU patients, 43 hospitals): randomized to three MRSA prevention strategies — targeted MRSA decolonization (screen + decolonize MRSA carriers), universal decolonization (all ICU patients, no screening), and surveillance + contact precautions. Results: universal decolonization (chlorhexidine bathing + intranasal mupirocin for MRSA carriers) produced 37% relative reduction in MRSA clinical cultures and 44% reduction in bloodstream infection from any pathogen — outperforming both targeted decolonization and surveillance + contact precautions. Universal ICU decolonization is now standard of care recommendation from SHEA/IDSA for ICUs with moderate-high MRSA endemic rates. Chlorhexidine bathing evidence: daily 2% chlorhexidine gluconate (CHG) bathing in ICU significantly reduces central line-associated bloodstream infection (CLABSI) and MRSA acquisition — multiple RCTs. Contact precautions for MRSA: CDC guidance now supports using contact precautions for MRSA-positive patients — gown and gloves for all patient care contacts. The benefit in endemic settings is well-established; contact precautions in settings with very low MRSA rates may have lower yield.
C. diff Prevention: Antibiotics, Environment, and Emerging Strategies
C. diff epidemiology: 462,000 cases/year in the US; 80% healthcare-associated or healthcare-facilitated; fluoroquinolone restriction in ASP programs has produced measurable C. diff reductions in multiple hospital systems. Primary prevention (most effective): antibiotic stewardship (restricting high-risk antibiotics — fluoroquinolones, clindamycin, broad-spectrum cephalosporins reduces C. diff rates 16–25%). Secondary prevention (contact precautions + environment): contact precautions (gown + gloves) for C. diff patients, private room placement, dedicated equipment. Environmental cleaning: C. diff spores are resistant to standard alcohol-based disinfectants — sporicidal agents (dilute bleach, peracetic acid, or chlorine dioxide) are required. Hypochlorite solution (1,000–5,000 ppm) significantly reduces environmental C. diff contamination. Bezlotoxumab (Zinplava): monoclonal antibody against C. diff toxin B — significantly reduces recurrence (17% vs. 27% placebo) when given with standard treatment in high-recurrence-risk patients. FMT (fecal microbiota transplantation): 80–90% success rate for recurrent C. diff — superior to vancomycin taper; now available as FDA-approved microbiome-based therapies (Rebyota, Vowst). For hospital infection control programs, our PPE catalog includes gowns, gloves, and isolation supplies, our medical gloves section provides the full range of examination and sterile gloves for contact precautions, and our wound care supplies support comprehensive infection control management.
